This is part #15 about Teva, the huge Israeli generics producer.Continue reading “Quicky #15 on Teva”
I instantly liked the company’s fundamentals, and its foreign ‘hidden’ character. It seems to fly very much under the radar when international investors are concerned. I generally believe this to be a real advantage and can be a strong investor’s edge.
Looking at the company more closely, I liked the vertically integrated business model. But I had to be careful, since I bought into a competitor some years ago. And that investment turned out …Continue reading “The world needs cheap high-quality generics. And investments! Hidden growing Krka might do …”